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ABSTRACT 
INTRODUCTION: Both hepatitis C virus (HCV) infection and diabetes 
mellitus (DM) are common illnesses with potentially devastating 
complications. There have been studies suggesting that HCV is a potential 
cause of diabetes by initially causing insulin resistance which then 
progresses to overt DM. 
STUDY DESIGN AND METHODS: Patients from the Diabetes Clinic at 
the Charlotte Maxeke Johannesburg Hospital were recruited to the study 
from January to November 2007. Both type 1 and type 2 diabetic patients 
were recruited and were compared to a group of first time, apparently 
healthy blood donors (data provided by the South African National Blood 
Services) for infection with HCV. Our patients were tested for HCV by the 
use of a rapid test device which detects the presence of HCV antibodies. 
Patients who were positive on antibody testing had a confirmatory PCR 
done. 
RESULTS: The prevalence of HCV infection was higher in our diabetic 
group than in the blood donors (1, 55% vs. 0, 02%; P=0, 0001; Odds ratio 
69; 95%CI; 22-212). Furthermore, the prevalence was higher amongst type 
2 than in the type 1 diabetic patients but this difference was not statistically 
significant (7/443(1, 58%) vs. 1/73(1, 37%) P= >0, 05). Five of the eight 
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patients who had a positive antibody test were also positive on PCR testing, 
and this was still statistically significant (5/516 (0.97%) vs. 8/35194; P 
=0.005). Previous exposure to recognized risk factors for HCV infection did 
not appear to be related to acquiring HCV. 
CONCLUSIONS: There appears to be a higher prevalence of HCV among 
patients with diabetes than in those without. Whether HCV has a direct 
causative role or not remains to be proven but there seems to be a link. 
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1. INTRODUCTION 
 
 
1.1 Epidemiology 
 
The rate of hepatitis C virus (HCV) infection has been gradually increasing 
over the years and currently an estimated 3% of the world’s population is 
infected. Because of such high numbers of infection, HCV has been declared a 
global health problem 1. The seroprevalence of HCV varies with different 
geographic locations with the highest reported prevalence rates in Africa and 
Asia and lower rates in North America, Western and Northern Europe and 
Australia 2 (See figure 1). The overall prevalence of HCV in Sub-Saharan Africa 
is estimated at 3%, with a higher prevalence in the central African region (6%) 
and lower rates in west Africa (2.4%) and southern and east Africa (1.6%)3. 
Egypt has an estimated population of 73 million and has the highest reported 
seroprevalence rate of 22% 3-4. The prevalence of HCV in South Africa is low 
with an estimated 2.6% of the population infected 5.There is also a risk of co-
infection with the human immunodeficiency virus (HIV) as some of the modes 
of transmission of these two viruses are similar. In countries such as India, 
rates of HCV/HIV co-infection vary according to route of transmission and 
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can range from 10-14% among persons reporting high risk sexual exposure to 
85-90% among those reporting intravenous drug use 6, 33.  
 
 
Figure 1: Global Prevalence of Hepatitis C  
 
 
Modified form Perz JF, Farrington LA, Pecoraro C: Estimated global prevalence of Hepatitis C virus 
infection. 42nd Annual meeting of the Infectious Diseases Society of America; Boston, MA,USA; Sept 
30-Oct 3, 2004. Data source: World Health Organization 
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1.2 Modes of Hepatitis C Transmission 
HCV is transmitted by parenteral routes such as through the use of blood 
products (blood and immunoglobulin transfusions from unscreened donors), 
injectable drug use, contaminated medical equipment including razor blades 
used by traditional healers, tattoo equipment, and rarely sexually or 
perinatally 7. Intravenous drug users have the highest prevalence of HCV 
infection, and the infection is thought to occur rapidly after initiating injecting 
drug behaviour 6, 40. 
 
1.3 Hepatitis C virus Genotypes 
HCV is a positive strand RNA virus and is the sole member of the 
hepacivirus genus, within the flaviviridae virus family 37, 38. Six HCV 
genotypes and multiple sub-types (1a, 1b etc) have been identified on the 
basis of molecular relatedness and one patient may be infected with more 
than one genotype 8, 9. Genotypes 1-3 have a world-wide distribution. 
Genotypes 1a and 1b are the most common, accounting for about 60% of 
global infections. In the United States and western Europe, genotypes 1a 
and 1b are most common 10,11, followed by genotypes 2 and 3. Genotype 4 is 
 4 
 
more common in Egypt 12, genotype 5 in South Africa 5 and genotype 6 in 
south east Asia. Changes of genotype from one to the other have also been 
noted in some studies of intravenous drug users 13, 14. This has significant 
treatment implications as responsiveness to treatment depends on the 
infecting genotype. Mixed infections of more than one genotype in a given 
patient has been documented 15.This will also have an impact on treatment 
as the duration differs depending on the infecting genotype.  
  
 
1.4 Pathogenesis of HCV Related Liver Disease 
 
The lack of animal models and of in vitro culture systems hampers the 
understanding of the pathogenesis of chronic HCV related liver disease. 
Hepatocellular injury from HCV is thought to result from host immune 
mediated responses to infection which may be non-specific such as 
interferon production or virus specific immune responses 15. The liver 
lesions are mainly a result of immune-mediated mechanisms, which are 
characterized by a type 1 T helper cell response 44. 
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Acute HCV infection is not clinically manifest in most patients and is most 
often diagnosed incidentally during routine medical checks for other 
illnesses. The disease onset is often assumed based on history of exposure 
to potential risk factors and some patients do not have a history suggestive 
of an acute hepatitic illness. Only a small proportion of patients (15-20%) 
are able to clear the acute infection, whereas most patients (80-85%) go on 
to develop chronic HCV infection 7, 41. Most of the chronically infected 
patients have relatively mild disease but 20-25% of them will develop 
cirrhosis and/ or hepatocellular cancer over the course of several decades 16. 
 
Secretion of cytokines such as interleukin 2, tumour necrosis factor (TNF) α 
and interferon (IFN) γ by CD4+ T lymphocytes activates antiviral 
mechanisms that can have a role in clearing the infection. CD 8+ cells 
might  be involved in direct killing of infected cells and might assist viral 
clearance  by secretion of cytokines such as IFNγ and TNF α12. The innate 
immune system also appears to play a role through recognition of pathogen 
associated membrane patterns via pattern recognition receptors like Toll 
like proteins. The discovery that NS3/A4 (a non-structural HCV protein) 
protease can interfere with the activation and nuclear translocation of 
interferon regulatory factor (IRF) suggested that HCV might interfere with  
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Toll Like Receptor( TLR) signaling, because IRF3 is an important 
downstream signal of TLR3, which senses double stranded RNA. 
Viral interference with innate immune recognition might contribute to the 
progressive loss of adaptive response to HCV during early chronic infection, 
and might provide a rationale for treatment based on the inhibition of the 
viral protease 7. 
 
Acquiring valid information on the natural history of chronic HCV is made  
difficult not only by the long duration needed to gather information but also 
by the fact that there may be accompanying factors that may modify the 
course such as antiviral treatment, co-infections with Hepatitis B (HBV) 
and HIV,  and concomitant alcohol use 16.Patients infected with HCV 
usually die from their co-morbid illnesses as opposed to the sequelae of 
infection with the virus itself. 
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1.5 Hepatitis C and Diabetes Mellitus 
 
There are millions of people suffering from DM and HCV and, both of them 
are two common disorders that have the potential to cause devastating 
long-term complications in a significant number of patients. 
HCV mainly targets the liver but it does not cause exclusive liver 
involvement. It has been associated with a wide range of extrahepatic 
manifestations including mixed cryoglobulinemia, glomerulonephritis, 
Porphyria Cutanea Tarda, Sjogren’s syndrome and autoimmune thyroiditis 
among others 17. Type 11 cryogobulinemia has been the most documented 
extrahepatic manifestation. The proposed mechanism is an autoimmune 
phenomenon where there is antigenic cross-reactivity between HCV and 
antigens encoded by the host genome and formation of immune complexes 
which are deposited in the different organs. Malignancies like 
hepatocellular carcinoma and Non-Hodgkins lymphoma are possible 
complications of chronic HCV infection 32. 
With regards to diabetes, a number of mechanisms have been shown to 
lead to insulin resistance and potentially diabetes mellitus in humans and 
animals infected with HCV. The potential mechanisms are as follows: 
 8 
 
 
1.5.1 Effects on the Insulin Signal Transduction Pathway 
When insulin binds to its receptor, it stimulates intrinsic tyrosine kinase 
activity, leading to receptor autophosphorylation and recruitment of  
intracellular signaling molecules such as insulin receptor substrates          
( IRS). This is followed by a cascade of events finally leading to 
translocation of glucose transporters (GLUT4) to the cell membrane, 
resulting in glucose uptake. Activation of other insulin receptor signaling 
pathways induces glycogen synthesis, protein synthesis, lipogenesis, and 
regulation of various genes in insulin responsive cells. 
 HCV consists of structural (core, E1, E2) and non-structural proteins 
NS2-NS5B 39. The HCV core protein has been shown to decrease 
expression of IRS 1 and IRS 2 in human hepatocytes 18. If the liver does 
not perceive the insulin signal, it will continue to produce glucose in the 
fed state leading to marked hyperglycemia and compensatory 
hyperinsulinemia. Elevated levels of pro-inflammatory cytokines like 
tumour necrosis factor (TNF) α and interleukin 6 have been 
demonstrated in patients with chronic HCV infection 41. HCV also down-
regulates insulin receptor substrates 1 and 2 through up-regulation of 
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suppressor of cytokine signaling 3 (SOCS3) and TNF α 18.19. IRS 1 and 2 
are important for insulin mediated glucose uptake and their down-
regulation results in insulin resistance and possibly overt diabetes            
(Figure 2). 
 
 One of the features of the metabolic syndrome is insulin resistance in 
addition to hypertension, dyslipidemia and central obesity 20. Patients 
chronically infected with HCV may develop insulin resistance without 
the other classical features of the metabolic syndrome 21. Insulin 
resistance has been shown in mice transgenic for the HCV core gene and 
after being fed a high-fat diet, these mice developed overt diabetes 
22.These findings suggest that body weight gain may trigger the process 
leading to overt diabetes. The insulin resistance leads to hepatic steatosis 
and promotes fibrosis progression in a genotype-dependent manner. 
Genotype 3 causes more extensive steatosis but lower insulin resistance 
than the other genotypes 23. With genotype 1, the steatosis seems to be 
an expression of the metabolic syndrome and the increased prevalence 
of diabetes in HCV has been shown to be predominantly among 
genotype 1 and 2-infected subjects 23,24. 
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Figure 2: HCV Induced Insulin Resistance 
 
 
 
Borrowed from Kazuhiko Koike: Hepatitis C virus infection can present 
with metabolic disease by inducing insulin resistance. A proposed 
mechanism of insulin resistance in HCV infection 25: HCV itself or elevated 
levels of cytokines such as TNF α may inhibit tyrosine phosphorylation of 
IRS-1 in the liver, suppress intracellular transduction of insulin signal and 
lead to insulin resistance. PKC=Protein Kinase C, MAPK=Mitogen-
activated protein kinase 
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1.5.2 Effects on the Pancreas: 
 There is evidence of pancreatic beta cell dysfunction in patients with 
HCV. Involvement of the pancreas by the virus results in morphological 
changes within the gland and altered islet cell function 26. The 
morphological changes are accompanied by reduced in vitro glucose-
stimulated insulin release, thus the virus is thought to be directly 
cytopathic to the pancreas. However an increase in apoptosis in the 
pancreas has not been demonstrated. 
 
 
1.6 Prevalence of Glucose Abnormalities in Patients with HCV 
 
The liver plays a key role in blood glucose control and thus a variety of 
acute and chronic liver diseases causing cirrhosis are associated with 
glucose abnormalities. However, the association of HCV infection and 
diabetes is higher than that expected by chance alone. Insulin resistance as 
determined by the homeostasis model assessment (HOMA-IR) has been 
demonstrated in chronic HCV patients lacking any evidence of liver 
injury23, 25. 
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In 1994, H Gray et al 27 assessed 200 British patients with type 2 diabetes 
and abnormal liver function tests, recruited from the United Kingdom 
Prospective Study of Diabetes (UKPDS) for Hepatitis C antibody positivity. 
The participants were divided into 100 white Caucasians, 50 Afro-
Caribbeans and 50 Asians. The findings indicated a high prevalence of HCV 
infection especially in Afro-Caribbeans (28%), followed by Caucasians 
(12%) and Asians (8%).This study suggested that abnormal liver functions 
in diabetic patients should not just be attributed to diabetes, and that HCV 
must be considered as a cause. 
 
In another study, Rafael Simo et al 28 compared a total of 176 diabetic 
patients to 6,172 blood donors, matched by recognized risk factors to 
acquire HCV infection. They found a higher prevalence of HCV in diabetic 
patients in comparison with blood donors (11. 5% vs. 2.5%;  P<0.001). They 
did not detect any particular epidemiological factor for HCV infection and 
most of the anti-HCV positive patients presented with abnormal liver 
function tests. 
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The question however, is whether HCV infection itself leads to diabetes or 
whether the HCV positive diabetic patients have inherent risk factors to 
develop diabetes despite being infected. Diabetic patients have a risk of 
being infected with HCV because of the frequent hospitalizations and 
possible exposure to unsterile needles when their fingers are pricked to test 
blood glucose levels.  
 
A prospective study done by Mehta et al 29 found an increased incidence of 
type 2 diabetes in persons with recognized diabetes risk factors and HCV 
infection compared with those with similar diabetes risk factors but not 
HCV infection . They suggest that pre-existing HCV infection may increase 
the risk of type 2 diabetes in persons with recognized diabetes risk factors. 
 
As glucose abnormalities can be seen in patients with any chronic liver 
disease, Chen et al 30 investigated the seroprevalence of HBV and HCV 
infections in type 2 diabetic patients. The diabetic patients were compared 
with a control group of subjects who came for medical check-ups. No 
significant difference was found between the type 2 diabetic patients and 
the control group for seropositivity of HBV surface antigen p=0.441. Anti-
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HCV seropositivity was detected in 6.8% of patients and 2.6% of the control 
subjects (OR=2.87, 95% CI: 1.51-5.46; P<0.001). 
2. Motivation for the Study 
 
Hepatitis C is a virus with a broad range of clinical manifestations, some of 
which are fatal like hepatocellular carcinoma. High prevalence rates have 
been noted in some parts of Africa whereas South Africa does not seem to 
be as much affected. South Africa however has high rates of other blood 
transmissible infections like HIV and hepatitis B, which is of concern as 
more and more cases of viral co-infections are being diagnosed.  
 
Diabetes is a common disease which carries significant morbidity and 
mortality. Insulin resistance due to a number of factors may progress to 
type 2 diabetes and that has been demonstrated in studies of animals and 
humans infected with HCV18-22. With newer therapies available and more 
being developed, HCV is one of the viruses that can potentially be fully 
eradicated. Treating HCV could theoretically reduce the number of patients 
developing HCV related diabetes mellitus and all the other extrahepatic 
manifestations associated with it. 
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3. Central Chapters 
 
3.1 Study Methods and Design 
 
For this study, patients attending the diabetes clinic at the Charlotte 
Maxeke Johannesburg Academic (CMJA) Hospital participated. Both type 1 
and type 2 patients over the age of 18 years were included and consecutively 
tested for HCV. The test kit used to test for the presence of HCV antibodies 
was the HCV Rapid Test device (Schering Plough (PTY) LTD), which is a 
point-of-care chromatographic immunoassay for the qualitative detection 
of antibodies to HCV in whole blood, serum or plasma. The sensitivity of 
the test is 98.5% and its specificity 97.3%. Its limitations were that it only 
provided qualitative detection of antibodies to HCV and secondly, a 
negative result did not preclude the possibility of HCV secondary to actual 
absence or inadequate quantities of such antibodies. The test was a finger 
prick test where a drop of blood was applied onto the test kit and results 
were read after a ten minute waiting period.  
 
Informed written consent (Appendix 2) was obtained from all participants 
before proceeding with the test. The patients were requested to complete a 
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questionnaire (Appendix 3) with the investigator to obtain details about 
their demographics, diabetes, body weight, height and exposure to 
recognized risk factors for HCV infection. The test results for the HCV were 
recorded on the questionnaire and patients were also informed about their 
results. The study population was made up of black, white, people of mixed 
and Asian descent (including Indians and Chinese). The information 
obtained was captured onto a spreadsheet using Microsoft Access®. 
 
The seroprevalence of HCV from the diabetic group was compared with 
that of the general population, which was made up of first-time, non-
diabetic blood donors. This group, supplied by the South African National 
Blood Services (SANBS), donated blood from January 2007-December 
2007 and they were divided into the black, white, mixed descent and Asian 
racial groups. The donated blood is routinely screened for blood- borne 
diseases and those found to be infected are rejected from the donor pool. 
The test used by the SANBS to screen for HCV is the Polymerase Chain 
Reaction (PCR). 
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Inclusion Criteria 
Age> 18 years 
Exclusion criteria 
Presence of diabetes in the blood donor group 
 
 
3.2 Statistical Analysis 
 
The data were captured using ACCESS database and analysis was done 
using STATA 9.0 Intercooled. Descriptive statistics for categorical variables 
was done using frequency distribution tables, reporting the frequencies and 
percentages. Continuous variables were described by mean values and 
standard deviations. 
 
 The prevalence of HCV for the diabetic group as well as the donor group 
was computed. The odds ratios of HCV for the diabetes group versus the 
donor group were computed with a 95% confidence interval. Further 
analysis on risk factors was done using Pearson’s Chi square and where 
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appropriate the Fischer’s Exact Test. Statistical significance was ascertained 
at the 5% level. 
Further analysis based on HCV PCR positivity between the diabetic group 
and the blood donor group was performed using the chi square test. A 
confidence interval of 95% with α=5% was chosen.  
 
3.3 Ethical Clearance 
Ethical clearance for the study was obtained from the University of the 
Witwatersrand’s Human Research Ethics Committee and is attached in the 
appendix 4. 
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4. RESULTS 
4.1 Clinical Characteristics of the Diabetic Patients: Table 1 
   
Diabetes Mellitus                       Type 1           Type 2 
Patient number N                    73            443 
Race Black              28            237 
Non-black      45            206 
Age Years              43±15            55±10 
Sex Males              29            179 
Females          44            264 
Diabetes Mellitus 
duration 
Years              20±15            9±7 
Treatment  Insulin            98.63% 
          
           72.1% 
Sulfonylurea   0%            100% 
Biguanides      0.44%            99.56% 
Glycated Haemoglobin 
% 
HbA1c            9.2±2            9±2 
Risk factors Blood T/F       6/73(8. 22%) 
 
       55/443(12.42%) 
Scarification   6/73(8.22%)         68/443(15.35%) 
Tattoos            3/73(4.11%)        15/443 (3.39%) 
IVDU              0/73 (0%)        1/443 (0.23%) 
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A total of 516 diabetic patients attending the diabetic clinic at the CMJA 
Hospital were recruited for the study. This group was made up of 73 type 1 
and 443 type 2 patients. Most of the patients were black, 265 versus 251 
non-black ( whites, mixed descent and Asians).  The type 1 patients were 
younger than the type 2 diabetes patients and they had had diabetes for a 
longer duration. Our study group composed of a higher number of females 
(308) and fewer males (208). Almost all the patients with type 1 diabetes 
required insulin alone. One patient was put on both insulin and a 
biguanide. The type 2 patients were on both biguanides and sulfonylureas 
and 72. 1% were insulin requiring due to poorly controlled diabetes on oral 
hypoglycemics.  
 
The mean glycated haemoglobin (HbA1c), which serves as a marker for 
glycaemic control, was about 9% for both groups. The recommended level 
for adults is <7% for macro- and microvascular risk reduction 35 and that 
level is used to guide treatment decisions.  
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Blood transfusions and traditional scarifications were the two high risk 
factors that most of our patients were exposed to (Graph 1). Only one 
patient from the type 2 group admitted to intravenous drug use. Only 18 
patients in total had tattoos. 
 
Figure 3: Risk Factors for HCV in Type 1 and Type 2 DM Patients 
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Table 2 compares the demographics of the diabetic patients who tested 
positive for HCV and those who tested negative. A total of eight patients 
were anti-HCV positive and that included one patient with type 1 DM and 
seven with type 2. There was no statistically significant difference in the 
patients’ ages, the type of diabetes nor the duration of the diabetes. None of 
the patients who were positive had tattoos or history of intravenous drug 
use but 12.5% had experienced traditional scarifications and 12.5% had 
received blood transfusions. 
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TABLE 2: Demographic Comparisons between the Diabetic 
Patients who are anti-HCV positive and anti-HCV negative 
 
 
  Anti HCV 
positive 
Anti-HCV 
negative 
P value 
Patients N 8 508  
Age Years 55±16 53±12 N/S 
Type of DM Type 1 1.37% 98.63% N/S 
Type 2 1.5% 98.42% N/S 
Duration of 
DM 
Years 8±5 11±9 N/S 
Risk factors Blood T/F 12.5% 11.81% N/S 
Scarification 12.5% 14.37% N/S 
Tattoos 0% 3.54% N/S 
IVdrug use 0% 0.2% N/S 
 
 
 
Exposure to recognized risk factors for HCV did not increase the rates of 
HCV infection. 
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We then compared our diabetic patients to the blood donor group for 
prevalence of HCV. We had a total of 35 194 people who donated blood in 
2007. This group was composed of 19 181 males and 16 013 females. There 
were 2 778 Asians, 3 165 black Africans, 2 011 persons of mixed descent and 
27 240 white people. There was an age difference between the diabetic 
patients and the blood donors but this was not statistically significant. 
There were 8 HCV positive patients from the blood donor group as well as 8 
from the diabetes group. 
 
TABLE 3: Comparison between the diabetic patients and the 
blood donors on antibody testing 
 
        
 Blood donors     Diabetic 
group 
P value 
n 35194 516  
Age in years 40±13.02 55±5 N/S 
Sex 
   Males 
   Females 
 
19181 
16013 
 
208 
308 
 
HCV Antibody 
Positive 
8/35194(0.02%)  8/516(1. 55%) <0.0001 
 25 
 
Our study demonstrated a higher prevalence of HCV in diabetes patients 
than in the blood donor group and that difference is statistically highly 
significant (1.55% vs. 0.02%; P<0.0001; odds ratio 69; 95%CI 22.5-212.4). 
As our patients had been tested for HCV infection with the use of a rapid 
finger prick test and not PCR, we invited them to our liver clinic for HCV 
PCR testing. Six out of the eight patients presented to the clinic. Two of the 
patients did not attend the clinic and, numerous attempts to contact them 
were unsuccessful. Five of the six patients were positive for HCV PCR and 
one was negative. This showed that at least one of our patients had a false 
positive result. Genotypes identified in four of the five patients were 1, 4a, 
and two patients with 5a.  
TABLE 3:Comparison between the diabetic patients and the 
blood donors on HCV PCR        
 Blood donors     Diabetic 
group 
P value 
n 35194 516  
Age in years 40±13.02 55±5 N/S 
Sex 
   M 
   F 
 
19181 
16013 
 
208 
308 
 
HCV PCR 
Positive 
8/35194(0.02%) 5/516(0.97%) 0.005 
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5. DISCUSSION 
 
HCV was found in 1.55% of our patients, a prevalence which is some 7.5 
fold greater than for the general South African population at large (1.55% 
vs. 0.02%; P <0.001; odds ratio 69;95% CI; 22-212). On PCR testing, the 
prevalence of HCV in our diabetic patients was 0.97%.  Our results support 
the recent evidence of an association between HCV and increased risk of 
developing diabetes. Simo et al28 found HCV infection in 11.5% of diabetic 
patients in comparison with 2.5% in blood donors. Gray et al27 also found a 
higher prevalence of HCV in diabetic patients, particularly so in Afro-
Caribbean participants. Our patient population was exposed to all the 
known risk factors for developing HCV, but previous exposure to these did 
not appear to significantly increase the rate of infection among them. Some 
of the patients who tested negative had used IV drugs in the past and even 
though that has been described as the commonest route of infection 
elsewhere 6, it was not the case in our setting. We hypothesize that the 
reasons for that difference is because IV drug use may not be as common a 
practice in RSA as it is in other countries or that there was exclusive use of 
injection paraphernalia in our subjects. Blood transfusions and traditional 
scarifications are the only two risk factors that our patients who tested 
positive for HCV were exposed to. Two of the type 2 diabetic patients had 
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both the blood transfusion and traditional scarifications and they were 
exposed to these risk factors before they developed diabetes. However, 
there was no statistically significant difference with regards to risk factors 
between those infected and those not (12.5% vs. 11.81% for transfusions and 
12.5% vs. 14.37% for scarifications). The blood donor group could not be 
compared to the diabetic with regards to risk factors for acquiring HCV as 
that data was not available from the blood bank records provided. The 
prevalence of HCV infection is low in South Africa 5, and that is also 
supported by the finding of a 0.02% prevalence rate in our blood donor 
group. Our diabetic patients were generally older than the blood donor 
group, but that difference was not statistically significant.  
 
Studies have shown an age effect on the chronicity of HCV with rates of 
30% in subjects below the age of 20 and 76% in those older than 20 years 
34. There was a higher prevalence of HCV infection in our type 2 diabetic 
group as compared to the type 1 diabetics, this was however not statistically 
significant. The duration of diabetes was almost similar in the two groups 
and both groups had had previous exposure to high risk behaviour for 
acquiring HCV. At this point in time, nothing points towards any particular 
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risk factor as being the cause of increased HCV prevalence in our diabetes 
patients.  
The natural progression of chronic HCV is that infected people only 
manifest clinical disease years after exposure to the virus 8. When recruited 
to participate in the study, the diabetic patients had no prior history of liver 
disease or current symptoms to suggest liver disease. A number of host and 
viral factors for accelerated disease progression have been identified and, 
amongst them are the presence of steatosis, insulin resistance, high fasting 
glucose and hyperinsulinemia 25, 45. These factors are often present in 
patients with DM and may predispose HCV infected patients to accelerated 
fibrosis and eventually cirrhosis. The risk of developing HCC for a patient 
with HCV-related cirrhosis is approximately 2-6% per year and HCC risk 
increases to 17-fold in HCV infected patients compared to HCV-negative 
subjects 46. 
 
This study cannot prove that HCV itself had any causative role in the 
development of diabetes mellitus. However, meta-analysis of studies 
reporting Hazards Ratios (HR) demonstrated that HCV infection 
significantly increases the risk of developing diabetes11. Numerous other 
studies have shown that chronic HCV infection is associated with insulin 
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resistance which can progress to overt diabetes. The proposed mechanisms 
include amongst others, activation pro-inflammatory mediators 18-19 and a 
direct involvement of the pancreas by the virus itself 26. 
 
 HCV infected patients have been shown to develop insulin resistance in the 
absence of other features of the metabolic syndrome. Clinical variables such 
as age, black ethnicity, male gender, cirrhosis or advanced histologic stage 
22, 27, 29, 36 are associated with development of diabetes in patients with 
chronic HCV. What is evident is that most of our patients had other risk 
factors for diabetes, for example black ethnicity and advanced age. Only 
one patient from the group of patients who tested positive agreed to have a 
liver biopsy. She was a 68 year old black lady whose histology showed 
features of chronic hepatitis with incipient cirrhosis, in keeping with 
chronic HCV infection.  
The study by Mehta et al 29 was a prospective analysis to examine if persons 
who acquired type 2 diabetes were more likely to have had antecedent HCV 
infection. Persons were categorized as low-risk or high-risk for diabetes 
based on their age and body mass index, factors that appeared to modify 
the type 2 diabetes-HCV infection incidence estimates. Among those at 
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high risk for diabetes, persons with HCV infection were more than 11 times 
as likely to develop diabetes ( relative hazard 11,58; 95%CI, 1.39-96.9). 
Among those at low risk, no increased incidence of diabetes was detected 
among HCV infected persons (relative hazard, 0.48; 95% CI 0.05-
4.40).From this study it appears that a combination of the known diabetes 
risk factors and infection with HCV (host and viral mediated factors 
respectively) places patients at a greater risk of diabetes.  
 
The mean body mass index (BMI) of our patients (not shown in the report) 
was 30.1 kg/m². Even though these patients had an inherent risk factor for 
diabetes shown by a high BMI, we believe that HCV had a role to play in the 
development of their diabetes. Wang et al 36 showed in a community-wide 
and population based cohort study, after adjusting for established risk 
factors for diabetes- age, gender, educational level, body mass index, 
smoking, and alcohol consumption- in a multivariate Cox proportional 
hazards analysis that persons with HCV infection had a significantly (70%) 
higher incidence of diabetes than those without HCV infection. This finding 
was consistent with other studies that showed that HCV infection is highly 
associated with diabetes. 
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6. Limitations of the Study 
 
1. We were not able to properly compare the diabetic group and the donor 
group with regards recognized risk factors for acquiring HCV as that data 
was not available.  
2. We were not able to perform confirmatory HCV PCRs in two of the 
patients who tested positive on the rapid antibody test and this has affected 
our final result. 
3. The confidence interval of the odds ratio for acquiring Hepatitis C 
infection among our diabetic cohort was wide and is likely the consequence 
of a small sample size. Greater precision should come from studying larger 
numbers. 
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7. Conclusion 
The study demonstrates a higher prevalence of HCV in our diabetic patients 
in comparison to the general population. It is however not possible to draw 
firm conclusions of whether HCV is a risk factor for diabetes. To do so we 
would need to follow up non-diabetic persons infected with HCV over a 
period of time and see whether they develop diabetes or not. In the interim, 
patients with chronic HCV should be monitored closely for abnormalities of 
glucose homeostasis. Likewise, patients with diabetes who develop 
abnormalities in liver function tests should be tested for infection with 
HCV. 
Finally, a study by Veldt et al 43 showed an increased risk of hepatocellular 
carcinoma in patients with HCV cirrhosis and diabetes. This highlights the 
need for surveillance for HCC in these patients and the need for education 
of the population at large about avoiding high risk behaviours for acquiring 
HCV and developing diabetes, as it might be possible to reduce the 
incidence of this aggressive malignancy by such means.    
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Introduction 
 
Hepatitis C was discovered in 1989 and affects approximately 170million 
people worldwide(1,2). Chronic Hepatitis C is a progressive condition and 
the spectrum of liver disease range from chronic inflammation, cirrhosis to 
hepatocellular carcinoma. 
 
 
 
Extrahepatic manifestations of chronic hepatitis C are clinically evident in 
nearly 40% of patients(2). Mixed cryoglobulinaemia, 
membranoproliferative glomerulonephritis and porphyria cutanea tarda, 
Sjogren’s syndrome, lymphoproliferative disorders and neuropathies are 
strongly associated with hepatitis C infection. The pathophysiologic basis 
for most of these syndromes seems immunologic(3). 
 
More recently, the association of insulin resistance and diabetes mellitus 
with chronic hepatitis C has been demonstrated. Data from several studies 
indicate that the prevalence of diabetes mellitus is high among patients 
with chronic hepatitis C(2,4,5,6).  
 
Chen et al did a study  in April 2006 to investigate the seroprevalence  of 
hepatitis B and C virus infections in type 2 diabetes mellitus patients. No 
significant difference was found between type 2 diabetes patients and the 
control group for seropositivity for HBsAg, but the rate of seropositive anti-
HCV was 2,8 times higher in type 2 diabetes patients than in non-diabetic 
control subjects(6). 
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Allison et al in a retrospective study  showed that the prevalence of diabetes 
in patients with chronic hepatitis C was 50% compared with 9% of the 
control population (7). 
 
Several clinical variables are associated with an increased prevalence of 
diabetes in patients with chronic hepatitis C. Some host factors include age, 
obesity, male gender, black ethnicity, alcohol consumption and a family 
history of diabetes(8). Hepatitis C is thought to cause diabetes through a 
variety of mechanisms including: 
 
 
1.It induces hepatic steatosis and increases tumour necrosis factor 
alpha, both    resulting in the development of insulin resistance and 
subsequent type 2 diabetes.(1,8) 
 
2. Hepatitis C encoded proteins might alter insulin signaling thus 
leading to impaired insulin sensitivity and glycemic dysregulation (9). 
 
3. Pancreatic beta cell dysfunction (8). 
 
 
Host and viral factors therefore may work synergistically to effect 
histopathologic change in the form of steatosis, inflammation, and fibrosis 
development. Once this occurs, data suggest that progression to diabetes 
may occur in patients with underlying genetic susceptibility(8). 
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Study Objectives 
 
1. To determine the seroprevalence of Hepatitis C in patients attending the 
diabetes clinic  
at Johannesburg Hospital. 
2. To compare the prevalence of hepatitis C in our type 2 diabetics with that 
in the case controls (healthy blood donors) 
3.The patients that test positive for hepatitis C will be assessed to see if they 
have any of the risk factors that are associated with the development of 
diabetes e.g.: obesity, alcohol consumption. 
4. The information will also be used to determine if previous exposure to 
high risk behavior for hepatitis e.g.: traditional scarifications, blood 
transfusions etc are associated with earlier onset of diabetes. 
5.The clinical records of those who test positive for hepatitis C will be used 
to see if the presence of diabetes is associated with more severe liver disease 
or not. Further surveillance for those patients will be at done at the liver 
clinic and there we will do a blood test for hepatitis C RNA .  
 
 
Methods 
 
All patients who attend the diabetes clinic at the Johannesburg hospital will 
be offered HCV screening. The sample will include all patients who are 
18yrs or older, from the black African, white, mixed descent and Asian 
racial groups. To control for selection bias, randomization will be done. 
Patients will be divided into the different racial groups and every third 
patient from the each group will be included into the study. 
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The seropositivity for hepatitis C will be determined by the use of testing 
kits which detect the presence of hepatitis C antibodies. The names of the 
test kits are Pegatest One step HCV test kit provided by Roche Products 
(pty) ltd and the hepatitis C testing kit from Schering Plough (pty) ltd . 
Capillary blood will be obtained by the finger prick method and a drop 
placed onto the testing kit. The result will be available within minutes. It is 
a rapid test and will be performed at the same time that the finger prick test 
for checking blood glucose is done.  
 
The test kit comes with easy instructions for interpretation but has these 
limitations: 
 
1. Only provides qualitative detection of antibodies to HCV. 
2. A negative result does not preclude the possibility of HCV infection 
secondary to actual absence or inadequate quantities of such 
antibodies.  
 
 
Specificity and Sensitivity 
 
Sensitivity – 98.5% 
Specificity – 97.3% 
 
All patients who undergo screening will have the results interpreted by 
diabetic clinic doctors and a HCV health questionnaire will be completed 
(see attached health questionnaire). 
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For case controls, healthy blood donors will be used. Records will be 
obtained from the South African blood transfusion services providing age, 
sex and race matched controls to compare with our study group. The age 
range from our case control will be +-5yrs.  
 
 
 
Data analysis 
 
A database will be set up to evaluate all the data obtained. Comparison will 
be made between the different race groups, type1 and type 2 diabetes and 
an age, sex and race matched group of healthy blood donors provided by Dr 
Crookes from the South African National Blood services. The age range 
from our case control will be ±5yrs. 
 
Statistical analysis will be performed using the Mann-Whitney test for 
comparison of continuous variables between groups and corrected chi-
squared method for qualitative data where appropriate. A two-tailed P-
value of <0.05 will be considered to be statistically significant.  
 
 
Ethics 
 
The patients participating in the study will be asked to sign an informed 
consent form explaining exactly what the procedure entails. Permission to 
carry out the study will also be requested from the head of the Department 
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of Medicine and the hospital superintendent. Participation will be on a 
voluntary basis and all the information captured will only be made known 
to the Wits University and the scientific community only. The study will be 
submitted to the ethics committee in August 2006. 
 
 
Timing 
 
The study will commence as soon as ethics approval has been obtained. The 
duration will be for a period 6 months. 
 
 
Funding 
 
The hepatitis C testing kits will be provided by pharmaceutical companies.  
Roche products (pty)ltd will provide the Pegatest one step HCV test kit and 
Schering Plough(pty)ltd will provide the Hepatitis C testing kit. 
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Appendix 2 
 PATIENT INFORMATION AND INFORMED CONSENT:  
 
Hello. My name is Dr Seabi and I work at the Department of Internal 
Medicine at the Johannesburg Hospital. 
 
I am doing a project to determine how many patients with Diabetes have 
evidence of exposure to a germ called “Hepatitis C virus”. The virus affects  
the liver and can cause ongoing inflammation, scarring or cancer of the 
liver. There have been reports that Hepatitis C can cause Diabetes. 
 
To carry out this study I will have to collect a drop of blood from you by 
using the “finger prick method”. This is the same method used routinely to 
check your blood glucose level at the clinic or at home. The blood collected 
will be applied on to the Hepatitis C testing kit to check if you are infected 
with the virus or not.  
 
The procedure will be carried out under sterile conditions but may result in 
some discomfort, pain or bleeding at the puncture site. 
 
It is up to you to decide whether or not to take part in this study. Whatever 
you decide, the standard of your future medical care will not be affected. 
Even if you do decide to take part, you are free to withdraw from the study 
at any time. Please note that the results of this study will be completely 
anonymous and your confidentiality will be maintained at all times. 
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Those who test positive for Hepatitis C will be offered further surveillance 
at the liver clinic where their progress will be monitored. 
 
You will not be paid to participate in this study and do so of your own free 
will 
__________________________________________________ 
 
I have been fully informed about the purpose and methods of this study 
and, in signing, agree to participate in the research. 
 
Name……………………………Signature………………….Date………..... 
 
Doctor…………………………..Signature…………………..Date…… 
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Appendix 3 
 
 
HEALTH QUESTIONNAIRE 
 
Please complete the following questionnaire 
 
 
Race : Black:  White:  Indian:  Other:  
 
Background: Rural:  Urban:    Rural/Urban:    
 
Height: ……………..meters  Weight: ……………Kg 
 
Type of Diabetes     
 
Duration of Diabetes:................years    
 
Diabetes Medication (Please list): 
 Oral:………………     Injectable……………………. 
     ……………………..    ……………………. 
     ……………………..    ………..…………... 
     ……………………..    …………………….  
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Most recent HbA1c: ……………….% 
 
Alcohol Consumption  Wine:  Spirits:   
  
 
  8-  5-21:    
       (<1/day) (1-2/day) (2-3/day) (>3/day)  
 
Have you had any of the following procedures? 
 
1. Blood transfusions:                                                   
(If yes: ? before 1990:   
2.  
3. Tattoos:     
4. Intravenous drug use:   
 
 
Hepatitis C result : 
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